Hypoglycemia Panel, Sulfonylureas Qualitative, Serum or Plasma

2010292
copy
 

Copy Utility


emailprint
Example Reports
Not Detected
Present

Icon

Additional Technical Information
Ordering Recommendation

Preferred test for evaluating if etiology of hypoglycemia is sulfonylurea ingestion.

Mnemonic
HYPOGLYPAN
Methodology

Qualitative Liquid Chromatography-Tandem Mass Spectrometry

Performed

Sun, Tue, Thu

Reported

1-6 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Plain red, gray (NaF/K Oxalate), green (Na Heparin), lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.4 mL)

Storage/Transport Temperature

Frozen. Also acceptable: Refrigerated.

Unacceptable Conditions

Separator tubes.

Remarks
Stability

Ambient: 48 hours; Refrigerated: 11 days; Frozen: 3 months

Reference Interval
Available Separately Drug Cutoff Concentration
No Glyburide 5 ng/mL
No Glimepiride 5 ng/mL
No Glipizide 5 ng/mL
No Repaglinide 5 ng/mL
No Nateglinide 5 ng/mL
No Acetohexamide 100 ng/mL
No Chlorpropamide 100 ng/mL
No Tolazamide 100 ng/mL
No Tolbutamide 100 ng/mL

Interpretive Data

This assay is used to evaluate hypoglycemia that may be caused from the ingestion of sulfonylurea drugs. Hypoglycemic drugs are detected (present) in this assay if the drug concentration is greater than the limit of detection (cut-off). The presence of hypoglycemic drug(s) indicates a recent ingestion.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
Hotline History

View Hotline History

 

Hotline History

Date of Change
Test Name Change
Methodology
Performance/Reported Schedule
Specimen Requirements
Reference Interval
Interpretive Data
Note
CPT Code
Component Change
Other Interface Change
New Test
Inactive
02/19/2019
X
X
N/A
CPT Codes

80377 (Alt code: G0480)

Are you an ARUP Client? Click here for your pricing.
Components
Component Test Code* Component Chart Name LOINC
2010293 Tolbutamide, Serum/Plasma 21567-3
2010294 Tolazamide, Serum/Plasma 21566-5
2010295 Repaglinide, Serum/Plasma 48328-9
2010296 Nateglinide, Serum/Plasma 49487-2
2010297 Glyburide, Serum/Plasma 48327-1
2010298 Glipizide, Serum/Plasma 48326-3
2010299 Glimepiride, Serum/Plasma 48325-5
2010300 Chlorpropamide, Serum/Plasma 48329-7
2010301 Acetohexamide, Serum/Plasma 43626-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Amaryl (Glimepiride)
  • Diabinese (Chlorpropamide)
  • Diabinese{R} (Sulfonylurea Hypoglycemics Panel (Qualitative), Serum or Plasma)
  • Dymelor (Acetohexamide)
  • Glucotrol (Glipizide)
  • Meglitinides
  • Micronase (Glyburide)
  • Orinase (Tolbutamide)
  • Prandin (Regaglinide)
  • Starlix (Nateglinide)
  • Tolinase (Tolazamide)
Hypoglycemia Panel, Sulfonylureas Qualitative, Serum or Plasma